Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer
Tanaka, S.; Uchino, J.
Translational Lung Cancer Research 8(Suppl 4): S369-S372
2019
ISSN/ISBN: 2218-6751 PMID: 32038917 DOI: 10.21037/tlcr.2019.06.05
Accession: 069798777
PDF emailed within 0-6 h: $19.90
Related References
Yue, D.; Xu, S.; Wang, Q.; Li, X.; Shen, Y.; Zhao, H.; Chen, C.; Mao, W.; Liu, W.; Liu, J.; Zhang, L.; Ma, H.; Li, Q.; Yang, Y.; Liu, Y.; Chen, H.; Wang, C. 2018: Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial LANCET. Respiratory Medicine 6(11): 863-873Azuma, K.; Hirashima, T.; Yamamoto, N.; Okamoto, I.; Takahashi, T.; Nishio, M.; Hirata, T.; Kubota, K.; Kasahara, K.; Hida, T.; Yoshioka, H.; Nakanishi, K.; Akinaga, S.; Nishio, K.; Mitsudomi, T.; Nakagawa, K. 2016: Phase Ii study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib Esmo Open 1(4): E000063
Lim, J.; Samuelsen, C.; Golembesky, A.; Shrestha, S.; Wang, L.; Griebsch, I. 2019: Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA Future Oncology 15(13): 1493-1504
Xiong, L.; Li, R.; Sun, J.; Lou, Y.; Zhang, W.; Bai, H.; Wang, H.; Shen, J.; Jing, B.; Shi, C.; Zhong, H.; Gu, A.; Jiang, L.; Shi, J.; Fang, W.; Zhao, H.; Zhang, J.; Wang, J.; Ye, J.; Han, B. 2019: Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: a Prospective, Single-Arm, Phase Ii Study Oncologist 24(2): 157-E64
Winther-Larsen, A.; Fynboe Ebert, E.B.; Meldgaard, P.; Sorensen, B.S. 2019: EGFR Gene Polymorphism Predicts Improved Outcome in Patients with EGFR Mutation-positive Non-small cell Lung Cancer Treated with Erlotinib Clinical Lung Cancer 20(3): 161-166.E1
Kishi, K.; Sakai, H.; Seto, T.; Kozuki, T.; Nishio, M.; Imamura, F.; Nokihara, H.; Satouchi, M.; Nakagawa, S.; Tahata, T.; Nakagawa, K. 2019: First-line onartuzumab plus erlotinib treatment for patients with MET-positive and EGFR mutation-positive non-small-cell lung cancer Cancer Treatment and Research Communications 18: 100113
Rosell, R.; Carcereny, E.; Gervais, R.; Vergnenegre, A.; Massuti, B.; Felip, E.; Palmero, R.; Garcia-Gomez, R.; Pallares, C.; Sanchez, J.M.; Porta, R.; Cobo, M.; Garrido, P.; Longo, F.; Moran, T.; Insa, A.; De Marinis, F.; Corre, R.; Bover, I.; Illiano, A.; Dansin, E.; de Castro, J.; Milella, M.; Reguart, N.; Altavilla, G.; Jimenez, U.; Provencio, M.; Moreno, M.A.; Terrasa, J.; Muñoz-Langa, J.; Valdivia, J.; Isla, D.; Domine, M.; Molinier, O.; Mazieres, J.; Baize, N.; Garcia-Campelo, R.; Robinet, G.; Rodriguez-Abreu, D.; Lopez-Vivanco, G.; Gebbia, V.; Ferrera-Delgado, L.; Bombaron, P.; Bernabe, R.; Bearz, A.; Artal, A.; Cortesi, E.; Rolfo, C.; Sanchez-Ronco, M.; Drozdowskyj, A.; Queralt, C.; de Aguirre, I.; Ramirez, J.L.; Sanchez, J.J.; Mo 2012: Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial LANCET. Oncology 13(3): 239-246
Yamamoto, N.; Seto, T.; Nishio, M.; Goto, K.; Yamamoto, N.; Okamoto, I.; Yamanaka, T.; Tanaka, M.; Takahashi, K.; Fukuoka, M. 2021: Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study Lung Cancer 151: 20-24
Shen, P.; Zhong, W. 2018: Adjuvant EGFR TKi therapy for resectable non-small cell lung cancer: new era for personalized medicine Journal of Thoracic Disease 10(3): 1364-1369
Payen, T.; Trédaniel, J.; Moreau, L.; Larivé, S.; Le Treut, J.; Nocent, C.; Hominal, S.; Grangeon, V.; Bizec, J.-L.; Molinier, O.; Debieuvre, D. 2021: Real world data of efficacy and safety of erlotinib as first-line TKi treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study Respiratory Medicine and Research 80: 100795
Okamoto, K.; Okamoto, I.; Hatashita, E.; Kuwata, K.; Yamaguchi, H.; Kita, A.; Yamanaka, K.; Ono, M.; Nakagawa, K. 2012: Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin Molecular Cancer Therapeutics 11(1): 204-213
De Marinis, F.; Vergnenegre, A.; Passaro, A.; Dubos-Arvis, C.; Carcereny, E.; Drozdowskyj, A.; Zeaiter, A.; Perez-Moreno, P.; Rosell, R. 2015: Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial Future Oncology 11(3): 421-429
Sakata, Y.; Kawamura, K.; Shingu, N.; Ichikado, K. 2016: Erlotinib plus bevacizumab as an effective treatment for leptomeningeal metastases from EGFR mutation-positive non-small cell lung cancer Lung Cancer 99: 120-122
Dillon, B.; Naidoo, B.; Knight, H.; Clark, P. 2012: NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer LANCET. Oncology 13(8): 764-765
Xie, Y.; Liang, J.; Su, N. 2015: Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer Nan Fang Yi Ke da Xue Xue Bao 35(3): 446-449
Ortega-Granados, A.L.; Artal-Cortes, Án.; Aguiar-Bujanda, D.; Oramas, J.; Fírvida, J.é L.; DE Castro, J.; Fuentes, J.C.; Gordo, R.ío.; Galán, R.; Trigo, J.é 2019: Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer Anticancer Research 39(3): 1317-1328
Atagi, S.; Goto, K.; Seto, T.; Yamamoto, N.; Tamura, T.; Tajima, K.; Inagaki, N. 2016: Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase Ii studies Future Oncology 12(18): 2117-2126
Isla, D.; De Castro, J.; Juan Vidal, O.; Grau, S.; Orofino, J.; Gordo, R.; Rubio-Terrés, C.; Rubio-Rodríguez, D. 2015: Adverse Events Costs Associated with Erlotinib or Afatinib in Non-Small cell Lung Cancer (Nsclc) Patients with Egfr Mutation-Positive Tumours Value in Health 18(7): A429
Zenke, Y.; Umemura, S.; Sugiyama, E.; Kirita, K.; Matsumoto, S.; Yoh, K.; Niho, S.; Ohmatsu, H.; Goto, K. 2016: Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer Lung Cancer 99: 1-3
Tani, T.; Naoki, K.; Yasuda, H.; Arai, D.; Ishioka, K.; Ohgino, K.; Yoda, S.; Nakayama, S.; Satomi, R.; Terai, H.; Ikemura, S.; Sato, T.; Soejima, K. 2019: A phase Ii trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patients Cancer ChemoTherapy and Pharmacology 84(5): 1065-1071